We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
PRA Health Sciences expanded its pharmacovigilance service to offer full post-marketing services for authorized COVID-19 vaccines and therapeutics, including post-authorization safety studies (PASS) delivered by Real World Solutions.
Icon, a company creating a new paradigm for bringing clinical research to patients, has agreed to acquire PRA Health Sciences Inc. in a cash and stock transaction valued at approximately $12 billion.
The Leukemia & Lymphoma Society (LLS) and PRA Health Sciences has announced a partnership to launch a global master clinical trial to develop new treatments for children with relapsed acute leukemia.